Biomarker for Duchenne Muscular Dystrophy

CompletedOBSERVATIONAL
Enrollment

103

Participants

Timeline

Start Date

August 20, 2018

Primary Completion Date

March 11, 2022

Study Completion Date

March 11, 2022

Conditions
Increased Lordosis/ScoliosisHyporeflexiaDuchenne Muscular DystrophyRed-Green Color BlindnessLordosisScoliosisMuscular AtrophyMuscular Weakness
Trial Locations (12)

10001

University Hospital Center Mother Teresa, Tirana

11566

Ain Shams University-Medical Genetics, Cairo

21131

Department of Pediatric,Faculty of Medicine, Alexandria University Children's Hospital, Alexandria

31527

Departmnet of Pediatrics, Tanta University, Tanta

54600

Department of Pediatric Gastroenterology and Hepatology, The Children's Hospital and Institute of Child Health, Lahore

300011

Lady Ridgeway Hospital for Children, Colombo

682041

Amrita Institute of Medical Sciences & Research Centre, Kochi

"Emergency Hospital for Children Louis Turcanu", Timișoara

Unknown

Ain Shams University, Cairo

Ain Shams Univirsity, Cairo

American of science and technology, Beirut

0177

Departmnet of Molecular and Medical Genetics, Tbilisi State Medical University, Tbilisi

All Listed Sponsors
lead

CENTOGENE GmbH Rostock

INDUSTRY

NCT02994030 - Biomarker for Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter